Precision medicine only works when execution delivers

For sponsors running complex, biomarker-driven trials, success depends on more than science. Our integrated ecosystem connects assays, data, patients and global operations — so your precision programs move forward with confidence.

Talk to a precision medicine expert

The promise of precision medicine comes with complex operational challenges

Fragmented biomarker strategies
Competition for the same small patient populations

Disconnected data
Siloed vendors across labs, clinical and manufacturing

The industry didn’t evolve its execution model — so trials are slower, riskier and less predictable than they should be. This isn’t a science problem. It’s a systems problem.

The PPD™ clinical research business of Thermo Fisher Scientific brings these pieces together into a closed-loop model, connecting assay development, clinical delivery, data integration, and global manufacturing into a single, coordinated system.

What you gain with an integrated precision medicine development model

Move from insight to execution seamlessly

Translate biomarker strategies into globally deployable clinical workflows

Find the right patients faster

Identify and enroll biomarker-defined populations with greater speed and accuracy

See risks before they impact timelines

Use AI-enabled forecasting and near-real-time monitoring to stay ahead of issues

Make decisions with confidence

Access harmonized, analysis-ready data across clinical, lab and real-world sources

Scale without complexity slowing you down

Align manufacturing, supply chain and clinical milestones from the start

Maintain scientific control without operational burden

Keep ownership of interpretation while execution is fully coordinated

Built for the complexity of modern precision medicine trials

0 +

biomarkers in the past five years

0 +

assays in the past two years

Global infrastructure spanning laboratories, clinical operations, digital platforms and manufacturing

Deep experience supporting biomarker-driven and multi-omics programs

Integrated delivery model connecting assay, data and execution at scale

Expert insights to strengthen your precision strategy

White Paper

Optimizing next-generation sequencing for precision oncology trials

Explore strategies that drive success in precision oncology to improve patient outcomes.

Blog Post

A new chapter in ALS drug development: How smarter trials and precision medicine are accelerating hope

Precision medicine and smarter trial design are accelerating ALS drug development and improving outcomes for patients.

Webinar

The Evolution of Precision Medicine in Age-Related Neurological Diseases

Learn how biomarkers and patient-centric strategies help advance treatment and trial design for older adults with neurological diseases.

Meeting with two professionals, one standing and another sitting at a desk.

A simplified, end-to-end approach to precision execution

Design with the end in mind Align biomarker strategy, assay readiness and clinical endpoints from the outset

Execute as one connected system Integrate labs, clinical operations, data and supply chain into a unified workflow

Optimize continuously with real-time insight Use AI-driven insights and harmonized data to reduce risk and improve predictability

Precision medicine questions & answers

How is this different from a traditional CRO model?

Most CROs operate across disconnected vendors. We deliver within a unified ecosystem that integrates labs, clinical operations, data and manufacturing.

Can you support global biomarker-driven trials?

Yes. Our infrastructure enables scalable assay deployment, global lab coordination and consistent data delivery across regions.

How do you help with patient recruitment in narrow populations?

We combine predictive analytics, site intelligence, and decentralized strategies to identify and enroll the right patients faster.

What role does AI play in your approach?

AI enhances — not replaces — scientific decision-making by improving forecasting, identifying risks early and accelerating trial execution.

Will we retain control of scientific decisions?

Absolutely. Sponsors maintain full ownership of scientific interpretation while we ensure operational excellence.

Can you support through commercialization?

Yes. Our model connects early development through manufacturing scale-up and distribution for continuity across the life cycle.

Precision Medicine